Radiant Research, the Cincinnati-based site management and clinical research company acquired by CRA Holdings in September 2012, has realigned its strategy to focus on its core site-services business following the sale of its contract research organization (CRO), Radiant Development, to fellow US company Accelovance.
“By exiting the CRO business, we are able to focus on operating and expanding our site network,” said Mark Hanley, chief executive officer of Clinical Research Advantage (the clinical-trial management arm of CRA Holdings) and Radiant Research.
CRA Holdings recently completed the sale of Radiant Development, a full-service CRO based in Chicago, Illinois, to privately held Accelovance for an undisclosed sum.
Working to refocus
Since Radiant Research was acquired by CRA Holdings, it has been working to refocus its efforts on its core site-services operations, Radiant noted.
“As an organisation that partners with many CROs, we did not want to compete with customers in our own space,” commented Hanley, adding that Accelovance and Radiant Development were “a perfect fit”.
Radiant plans to maintain its ongoing relationship with Accelovance by partnering with the CRO to conduct high-quality clinical trials, he pointed out.
When CRA Holdings acquired Radiant Research, it became the “largest and most therapeutically diverse” clinical-trial site network in the US, Radiant said. The two companies run 57 trial sites in total and have “aggressive plans” for continued site expansion throughout 2013.
Radiant sites claim a 98% enrolment rate (defined as the number of participants enrolled in a study divided by the number of participants contracted), placing the network among the top 5% of research sites in the US, it added.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.